A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects

Summary

A randomized, double-blind, placebo-controlled trial design was used to assess the safety, tolerability, pharmacokinetics and pharmacodynamics characteristics, and immunogenicity of TQH2722 injection in healthy subjects.

Timeline

Start

2022-06

Primary completion

2023-06

Completion

2023-08

Publications

• Li X, Wang X, Zhu S, Sun F, Fu Y, Ban R, Tan H, Yin Z, Gao Z, Xu Z, Yu D, Cao Y. Safety, pharmacokinetics and population pharmacokinetic model of TQH2722, a novel IL-4Ralpha monoclonal antibody in healthy subjects: a phase I, first-in-human, single-dose and multiple-dose escalation study. J Pharm Sci. 2025 Jul;114(7):103773. doi: 10.1016/j.xphs.2025.103773. Epub 2025 Apr 10.

Drugs

Indications